DermoSafe announced the closing of an agreement with a private investor for a seed round of more than half a million CHF, with a possible funding increase totalling more than 1 million CHF during the upcoming years.
DermoSafe’s aim is to bring innovative products and services for the early detection of melanoma and management to the market by democratize dermoscopy. Dermoscopy is a method used by most dermatologists for the identification of skin cancers. It enables a deeper view of the skin for a better performance compared to a naked eye exam.
“We are particularly happy to bring this new investor on board as he brings his medical expertise and experience as a medical doctor. He therefore has a full understanding of the value of our concept and of what it brings to all stakeholders in the healthcare ecosystem. This is a major milestone achieved by DermoSafe and it will definitely help to reach our vision, mission and goals”, writes DermoSafe CEO Philippe Held in a blog post on LinkedIn.
Digital dermoscopy will become sooner or later as broadly used as stethoscopes or thermometers in the medical world. However, the assessment of what becomes visible deeper in the skin with dermoscopy will always require a high level of specialization, expertise and experience. As the DermoSafe team plan to democratize its use, one of DermoSafes missions is to bring that expertise closer to the patient by combining human and artificial intelligence through integrated solution and services.
(Blog post, SK)
Please login or sign up to comment.
Commenting guidelines